Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

This is an interventional treatment trial for Presumed Ocular Histoplasmosis (POHS) focused on measuring Histoplasmosis Read More

Inclusion Criteria:

• Subfoveal CNV due to presumed ocular histoplasmosis of less than 1 year duration
• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age greater than or equal to 21 years of age
• CNV lesion of than < 5400 microns in diameter
• Best corrected visual acuity of 20/40-20/320
• Birth control therapy for females of child-bearing potential

Exclusion Criteria:

• Subfoveal NCV due tp presumed ocular histoplasmosis for > 1 year
• Pregnancy or lactation premenopausal women not using adequate contraception
• Prior enrollment in the study
• Any other condition that the Investigator believes would pose a significant hazard to the subject
• Participation in another simultaneous medical investigation or trial
• Participation in another trial or previous trial of ranibizumab or Avastin
• Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that could require medical or surgical intervention or ifa allowed to progress, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period
• Previous panretinal photocoagulation
• Previous steroids or PDT in 3 months
• Previous participation in any studies of investigational drugs within 30 days preceding Day 0
• Prior participation in a Genentech ranibizumab clinical trial
• Previous treatment with intravitreally (in either eye) or intravenously administered Avastin within 3 months
• Previous use of Macugen in the study eye within 3 months
• Prior submacular surgery